McGeorge Anne
SEC CIK 1779934 · EDGAR
BoughtSold
Most active insiders at DNTH, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Garcia Marino | CEO AND Pres, Dir | — | $27.96M |
| 2 | Randhawa Simrat | EVP, Head of R, D | — | $15.00M |
| 3 | Savitz Ryan | EVP, CFO, CBO | — | $14.29M |
| 4 | CARR EDWARD | CAO | — | $5.59M |
| 5 | Veness Adam M | SVP, GC, Sec | — | $4.63M |
| 6 | Soteropoulos Paula | Dir | — | $2.25M |
| 7 | McGeorge Anne | Dir | — | $844.8K |
| 8 | Read Simon | Dir | — | $630.8K |
Transactions 9
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-11 17:15 | 2026-08-10 | DNTH | Dianthus Therapeutics, Inc. /DE/ | McGeorge Anne | Dir | M - OptEx | $12.52 | +7,750 | 7,750 | New | +$97.0K |
| DMT | 2026-08-11 17:15 | 2026-08-10 | DNTH | Dianthus Therapeutics, Inc. /DE/ | McGeorge Anne | Dir | S - Sale+OE | $109.01 | -7,750 | 0 | -100% | -$844.8K |
| 2026-07-29 18:54 | 2026-07-27 | STLN | Starling Oncology, Inc. | McGeorge Anne | Dir | A - Grant | $0.00 | +41.2K | 332.5K | +14% | $0 | |
| M | 2025-11-24 | 2025-11-20 | STLN | Starling Oncology, Inc. | McGeorge Anne | Dir | A - Grant | $0.00 | +108.0K | 291.4K | +59% | $0 |
| 2024-11-25 | 2024-11-22 | STLN | Starling Oncology, Inc. | McGeorge Anne | Dir | A - Grant | $0.00 | +56.0K | 183.3K | +44% | $0 | |
| 2023-12-28 | 2023-12-26 | STLN | Starling Oncology, Inc. | McGeorge Anne | Dir | A - Grant | $0.00 | +56.0K | 127.3K | +78% | $0 | |
| 2023-03-21 | 2023-03-17 | STLN | Starling Oncology, Inc. | McGeorge Anne | Dir | A - Grant | $0.00 | +26.2K | 71.3K | +58% | $0 | |
| 2022-11-21 | 2022-11-17 | STLN | Starling Oncology, Inc. | McGeorge Anne | Dir | A - Grant | $0.00 | +22.7K | 45.1K | +101% | $0 | |
| M | 2022-03-23 | 2022-03-21 | STLN | Starling Oncology, Inc. | McGeorge Anne | Dir | A - Grant | $0.00 | +22.4K | 22.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations